tiprankstipranks
Trending News
More News >
Keymed Biosciences, Inc. (HK:2162)
:2162
Hong Kong Market

Keymed Biosciences, Inc. (2162) AI Stock Analysis

Compare
1 Followers

Top Page

HK

Keymed Biosciences, Inc.

(2162)

Rating:52Neutral
Price Target:
Keymed Biosciences, Inc. exhibits strong revenue growth and positive market momentum, which are significant strengths. However, the lack of profitability, negative cash flows, and high valuation risks weigh heavily on the overall stock score. The company's robust balance sheet provides some stability, but the path to profitability is crucial for future performance.

Keymed Biosciences, Inc. (2162) vs. iShares MSCI Hong Kong ETF (EWH)

Keymed Biosciences, Inc. Business Overview & Revenue Model

Company DescriptionKeymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
How the Company Makes MoneyKeymed Biosciences, Inc. generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company's revenue streams include product sales upon receiving regulatory approval and successful market entry of its therapeutics. Additionally, Keymed may engage in strategic partnerships and collaborations with other pharmaceutical companies, which can result in milestone payments and royalties. The company also invests in research and development to expand its pipeline, aiming to increase future revenue potential as more products advance through clinical trials and reach the market.

Keymed Biosciences, Inc. Financial Statement Overview

Summary
Keymed Biosciences, Inc. is in a growth phase with increasing revenues. However, it faces challenges with profitability and positive cash flows. The company has a strong balance sheet with low leverage but negative cash flows and net losses raise concerns about financial sustainability. Investment in growth is evident, but profitability remains a concern.
Income Statement
35
Negative
Keymed Biosciences, Inc. has shown significant revenue growth from 2022 to 2024, with revenue increasing from 100 million to 428 million. However, the company is still operating at a loss, with a negative net profit margin and EBIT margin. The gross profit margin is high, indicating good product profitability, but this is offset by high operating expenses leading to negative net income.
Balance Sheet
50
Neutral
The company maintains a strong equity position with a debt-to-equity ratio below 0.5, indicating low leverage. However, the ROE is negative due to consistent net losses. The equity ratio is healthy, suggesting a strong asset base compared to liabilities, which is crucial for future growth and stability.
Cash Flow
30
Negative
The free cash flow remains negative, reflecting high capital expenditures and operating losses. There is an absence of operating cash flow, highlighting challenges in converting revenue into cash. The company has not demonstrated positive cash flow to net income ratios, which are critical for long-term financial health.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
428.12M354.10M100.06M110.27M0.00
Gross Profit
415.92M317.22M97.48M93.07M0.00
EBIT
-618.10M-434.80M-295.38M-3.88B-804.70M
EBITDA
-574.46M-269.77M-259.25M-3.86B-785.71M
Net Income Common Stockholders
-515.24M-359.36M-308.12M-3.90B-832.73M
Balance SheetCash, Cash Equivalents and Short-Term Investments
2.16B2.72B3.18B3.52B354.08M
Total Assets
3.77B3.88B3.93B3.93B529.95M
Total Debt
753.24M418.71M121.97M39.26M66.86M
Net Debt
334.82M-432.32M-482.10M-1.48B-132.54M
Total Liabilities
1.29B896.11M593.10M289.07M1.62B
Stockholders Equity
2.47B2.99B3.34B3.65B-1.09B
Cash FlowFree Cash Flow
0.00-686.23M-681.48M-387.50M-139.26M
Operating Cash Flow
0.00-303.62M-401.93M-214.64M-119.36M
Investing Cash Flow
0.00468.20M-645.59M-2.04B-113.07M
Financing Cash Flow
0.0072.13M-8.06M3.64B7.40M

Keymed Biosciences, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price47.80
Price Trends
50DMA
43.08
Positive
100DMA
38.26
Positive
200DMA
38.16
Positive
Market Momentum
MACD
1.29
Negative
RSI
68.34
Neutral
STOCH
91.80
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2162, the sentiment is Positive. The current price of 47.8 is above the 20-day moving average (MA) of 42.47, above the 50-day MA of 43.08, and above the 200-day MA of 38.16, indicating a bullish trend. The MACD of 1.29 indicates Negative momentum. The RSI at 68.34 is Neutral, neither overbought nor oversold. The STOCH value of 91.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2162.

Keymed Biosciences, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
52
Neutral
HK$12.51B-18.87%16.35%-49.63%
$12.78B29.758.17%
59
Neutral
HK$3.76B21.094.47%-9.75%
51
Neutral
HK$33.02B-56.68%52.25%11.46%
50
Neutral
HK$73.83B-8.98%-54.66%-123.11%
48
Neutral
HK$10.61B-4.41%94.98%85.69%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2162
Keymed Biosciences, Inc.
49.60
16.60
50.30%
WXIBF
Wuxi Biologics (Cayman)
3.38
1.97
139.72%
HK:9926
Akeso, Inc.
87.25
48.55
125.45%
HK:9995
RemeGen Co. Ltd. Class H
46.20
20.35
78.72%
HK:1873
Viva Biotech Holdings
1.82
1.18
184.38%
HK:6185
CanSino Biologics, Inc. Class H
35.50
13.70
62.84%

Keymed Biosciences, Inc. Corporate Events

Keymed Biosciences Announces 2025 Annual General Meeting and Key Resolutions
Apr 28, 2025

Keymed Biosciences Inc. has announced its upcoming Annual General Meeting scheduled for June 26, 2025, in Chengdu, China. The meeting will address several key resolutions, including the adoption of the 2024 financial statements, re-election of directors, and re-appointment of Ernst & Young as auditors. Additionally, the company seeks approval for the directors to issue new shares, which could impact its market position by potentially increasing capital for future projects.

Keymed Biosciences to Review Annual Results and Dividend
Mar 12, 2025

Keymed Biosciences Inc. has announced a board meeting scheduled for March 24, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024, and to consider the payment of a final dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.

Keymed Biosciences Gains Approval for Stapokibart in Allergic Rhinitis Treatment
Feb 7, 2025

Keymed Biosciences, Inc. announced that China’s National Medical Products Administration has approved the supplemental New Drug Application for Stapokibart, a humanized antibody, for the treatment of seasonal allergic rhinitis. This approval is based on a successful phase III study showing Stapokibart’s efficacy and safety in controlling nasal and ocular symptoms. This development marks Stapokibart as the first domestically manufactured IL-4R α antibody drug granted marketing approval, which could enhance Keymed’s positioning in the biopharmaceutical market.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.